Is ketamine FDA-approved for PMDD?

No. Ketamine is FDA-approved as an anesthetic; its use for PMDD is off-label. SSRIs such as sertraline, fluoxetine, and paroxetine are FDA-approved for PMDD and are considered first-line treatment per DSM-5-TR and ACOG guidelines. Hormonal options including combined oral contraceptives and GnRH analogs are also first-line. Ketamine is reasonable to consider when those approaches have not provided adequate relief.

Would I get infusions only during the luteal phase of my cycle?

A cycle-timed approach is biologically plausible because PMDD symptoms cluster in the luteal phase, and some clinicians experiment with timing infusions accordingly. The honest answer is that the optimal cadence has not been established in any large trial. Most patients we see start with a standard induction series and then track symptoms across two or three cycles to decide whether luteal-phase boosters make sense for them.

What if I'm already taking a continuous SSRI for PMDD?

Most SSRIs combine safely with ketamine in a clinical setting. A 2017 review by Andrade in The Journal of Clinical Psychiatry found no consistent evidence that SSRIs blunt ketamine's antidepressant effect. Do not stop your SSRI to try ketamine. We coordinate with your prescribing provider so any medication adjustments are made deliberately and only when clinically indicated.

Is hormonal therapy still the better first move?

Yes. SSRIs, combined oral contraceptives containing drospirenone, hormonal IUDs, and GnRH analogs are all considered first-line per DSM-5-TR and ACOG. They have decades of evidence and are FDA-approved or guideline-endorsed for PMDD. Ketamine is a reasonable conversation when first-line treatments have failed or produced intolerable side effects, and we would want to see those options tried thoughtfully before recommending an off-label approach.

Ketamine for PMDD: Small Evidence Base, Real Biological Rationale

Q: Can ketamine address the rage and irritability of PMDD, not just the sadness?

The anxiety and irritability literature may be more applicable to PMDD than the pure depression literature. A 2017 study by Glue and colleagues in the Journal of Psychopharmacology found 10 of 12 patients with treatment-refractory generalized and social anxiety responded to ketamine, with anxiolytic effects lasting up to seven days. PMDD's irritability and rage components share neurobiology with anxiety, so this evidence is relevant even though it is not PMDD-specific.

What PMDD actually is, and why the “bad PMS” framing fails patients

PMDD is a distinct depressive disorder in the DSM-5-TR, classified alongside major depression rather than tucked into the gynecological literature. The diagnostic criteria require a cluster of mood, anxiety, and physical symptoms that begin in the luteal phase of the menstrual cycle, peak in the days before menses, and remit fully within a few days of bleeding. The American Psychiatric Association estimates PMDD affects between 3% and 8% of menstruating people. That is millions of patients in the United States alone.

The cyclical pattern is what makes PMDD biologically distinct. Symptoms are not chronic; they arrive on schedule, dismantle a person’s functioning for one to two weeks, and then lift. Many patients describe losing roughly a quarter of every month to depression, irritability, rage, anxiety, sleep disruption, food cravings, and a sense of being unable to recognize themselves. Relationships strain. Careers stall. The pattern is so reliable that some patients track it on a calendar for years before anyone names it.

Calling this “bad PMS” is not just inaccurate. It actively delays care. PMDD has elevated rates of suicidal ideation in the late luteal phase, and the diagnosis is associated with significant occupational and relational impairment. Treating it as a real psychiatric condition is the starting point for any honest conversation about therapy, including conversations about ketamine.

The biology that makes ketamine plausible in PMDD

The current best-supported theory of PMDD is that affected patients have a heightened central nervous system sensitivity to normal cyclical fluctuations of allopregnanolone, a metabolite of progesterone that modulates GABA receptors. The hormone levels themselves are not abnormal. The brain’s response to those normal shifts is. Imaging and pharmacological studies increasingly point to glutamatergic involvement in this dysregulation, particularly in the prefrontal cortex and limbic circuits.

Ketamine is an NMDA receptor antagonist that drives a downstream surge in glutamate signaling and AMPA receptor activation, which is one mechanism researchers credit for its rapid antidepressant effects. A 2018 paper by Ho, Correia, and Ingle in Biochemical Pharmacology proposed an additional layer: ketamine and its metabolites act as estrogen receptor ligands and modulate AMPA glutamate receptor expression. That provides at least a hypothetical bridge between cycle-driven hormone shifts and ketamine’s mood effects, which is exactly the territory PMDD lives in.

None of this proves ketamine works for PMDD. It establishes that the mechanism is not random. The drug acts on systems that the PMDD literature has independently flagged as involved in the disorder. Mechanistic plausibility is not the same as clinical evidence, but it is more than nothing.

What evidence exists in PMDD specifically

This is the part that deserves honesty. There is no large randomized controlled trial of ketamine in PMDD. There are scattered case reports, small open-label observations, and clinician commentary in the women’s mental health literature. Anyone telling you the PMDD-specific evidence base is robust is overstating it.

What we do have is a body of work on related populations. Clinicians who treat PMDD often draw on three adjacent literatures: ketamine in major depressive disorder, ketamine in treatment-resistant anxiety, and ketamine in postpartum and perimenopausal depression, where hormonal context is part of the picture. Those literatures are stronger, and they shape how thoughtful clinics think about offering ketamine to patients whose PMDD has not responded to first-line care.

Ketamine is FDA-approved as an anesthetic; its use for PMDD is off-label. Spravato (esketamine) is FDA-approved for treatment-resistant depression and for major depressive disorder with acute suicidal ideation, not for PMDD specifically. Any clinician offering ketamine for PMDD should be transparent about that framing.

The bigger picture: depression, anxiety, and women’s mental health data

Multiple randomized trials and meta-analyses across the 2010s and 2020s have established that IV ketamine produces rapid, clinically meaningful reductions in depressive symptoms in patients with treatment-resistant depression, often within 24 hours and with effects lasting days to a few weeks per session. That literature is the backbone of why ketamine is offered at all, and it is directly relevant to the depressive component of PMDD.

The anxiety and irritability profile of PMDD — the rage, the sense of being unable to tolerate small frustrations, the panic — may track even more closely with the ketamine-for-anxiety literature. A 2017 study by Glue and colleagues in the Journal of Psychopharmacology treated 12 patients with treatment-refractory generalized and social anxiety using ketamine at 0.5 to 1 mg/kg. Ten of twelve responded, with anxiolytic effects lasting up to seven days. PMDD’s irritability component is not identical to generalized anxiety, but it shares enough underlying biology that this evidence is part of the conversation. Our broader writeup on ketamine for anxiety covers that data in more detail.

Women’s mental health is also where adjacent off-label uses are most actively studied. Postpartum depression and perimenopausal depression are both contexts where hormonal state appears to interact with ketamine’s antidepressant effect. PMDD is not the same condition as either, but the family resemblance is real, and the same clinicians who treat one often treat the others.

First-line treatments to try first

Both the DSM-5-TR and the American College of Obstetricians and Gynecologists identify SSRIs and ovulation suppression as first-line for PMDD. That guidance reflects decades of evidence and should not be skipped on the way to anything off-label. The standard options include:

SSRIs, continuous or luteal-phase dosing. Sertraline, fluoxetine, and paroxetine are FDA-approved for PMDD. Some patients take them daily; others only for the second half of each cycle. SSRI response in PMDD often appears within days rather than the weeks typical of major depression, which is itself an interesting biological clue.
Combined oral contraceptives. Pills containing drospirenone in a 24/4 regimen have evidence for reducing PMDD symptoms by suppressing ovulation.
Hormonal IUDs and other ovulation-suppressing strategies. Used selectively, these can flatten the cyclical hormonal driver.
GnRH analogs with add-back therapy. Reserved for severe, refractory PMDD; effective but more involved.
Cognitive behavioral therapy and lifestyle stabilization. Sleep, exercise, alcohol, and tracking the cycle all matter, and they matter more in PMDD than in conditions without a luteal trigger.

If you have not worked through these options with a knowledgeable provider, that is the right place to start. Ketamine is not a substitute for adequate trials of treatments that already have FDA approval and guideline endorsement for your specific diagnosis.

Where ketamine might fit, and where it should not

The honest framing for ketamine in PMDD is this: we are usually treating the comorbid treatment-resistant depression that PMDD can become, not PMDD as a primary indication. When patients have cycled through SSRIs, hormonal options, and therapy and still lose two weeks out of every month to depressive symptoms with active suicidality at the worst points, ketamine becomes a reasonable conversation. The mechanism is plausible. The adjacent evidence is meaningful. The risk profile in monitored settings is well characterized.

Ketamine is not a fit for everyone with PMDD. It is not first-line. It is not a replacement for SSRIs or hormonal therapy. We do not stop your existing medications to start ketamine. Research suggests most SSRIs combine safely with ketamine, and a 2017 review by Andrade in The Journal of Clinical Psychiatry found no consistent evidence that SSRIs blunt ketamine’s antidepressant effect, so the realistic plan for many patients is layered, not substitutive.

For the underlying depressive component, our writeup on depression treatment covers how ketamine fits into a broader psychiatric plan, and our overview of anxiety treatment covers the irritability and panic side. Both pages assume the same off-label framing applies.

What an integrated PMDD plan looks like at our clinic

If a patient with PMDD-driven treatment-resistant depression comes to us, the conversation begins with what has already been tried and how rigorously. We want to see that SSRIs have been given an adequate trial, that hormonal options have been considered with a gynecologist or psychiatrist, and that a cycle-tracking record exists. Without that record, we cannot tell whether symptoms are luteal-phase locked or whether something else is happening.

If ketamine is reasonable, we typically start with a standard induction series and ask the patient to track symptoms across two or three cycles. Some patients respond enough to the induction that ongoing maintenance is straightforward. Others benefit from cycle-timed boosters in the late follicular or early luteal phase, though we want to be clear the optimal cadence is not established in any large trial. We are doing thoughtful clinical adjustment, not following a validated protocol.

Marla Peterson, CRNA, oversees every infusion with anesthesia-level monitoring — continuous pulse oximetry, blood pressure, and heart rate — with a CRNA in the room and available throughout. The setting is quiet, private, and designed to feel less like a hospital than like a serious clinical space that respects what you are bringing into the room. Walter White and Wilma, our therapy dogs, are part of that environment for patients who want them to be.

Sessions at Music City Ketamine are $475 each, and insurance generally does not cover off-label uses. We are direct about cost from the start so the financial picture is part of the decision, not a surprise. For a deeper look at the underlying pharmacology, our explainer on how ketamine works covers the mechanism in plain language.

Honest expectations

Several things deserve to be said clearly. The PMDD-specific evidence is small. Studies indicate ketamine may help when first-line treatments have failed, but there is no body of randomized data we can point to as definitive for this diagnosis. Not everyone responds. Some patients find that addressing the depressive component changes how the cycle feels even though the cyclical pattern itself remains. Others find ketamine does not move the needle, in which case continuing to invest in it is not the right answer.

We do not promise outcomes. We do not encourage anyone to stop or change a working medication on their own. If you are on an SSRI or hormonal therapy, those decisions belong to your prescribing provider, and we coordinate rather than override. If PMDD has cost you years of stable months, the goal is to build a plan that takes the biology seriously and treats this as the legitimate psychiatric condition it is.